{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086127","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.076291+00:00","generated_at":"2026-05-31T12:40:27.472564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Nuvectis Q2 2024 net loss narrows to $4.4M; progressing NXP800 and NXP900 trials","bullets":["Cash $18.1M at June 30, 2024, down $1.4M from March 31, 2024; net loss $4.4M vs $5.8M YoY.","R&D spend $2.9M (-33% YoY); G&A $1.7M (+13%); interest income $0.2M.","NXP800 Phase 1b ovarian cancer trial enrolling at ~15 US/UK sites; update due fall 2024.","NXP800 investigator-sponsored cholangiocarcinoma trial recruiting; update expected by end of 2024.","NXP900 dose escalation: 3 cohorts complete, no DLTs; planning combo with EGFR/ALK inhibitors in NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086127","json":"https://secwatch.observer/filing/0001104659-24-086127.json","markdown":"https://secwatch.observer/filing/0001104659-24-086127.md","text":"https://secwatch.observer/filing/0001104659-24-086127.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924086127/0001104659-24-086127-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465924086127/tm2420911d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:40:27.472564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}